VIVES is a multi-sector fund that invests in projects with a positive societal impact
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models.
With the...
The result of more than 15 years of research in the university laboratories of UCLouvain and multiple collaborations (ELEN department, ICTEAM), the VOCSens spin-off is developing a new concept of...
To meet the growing demand for agricultural production, traditional production methods will have to be complemented by new technologies that not only improve crop yields, but also increase their...
Michel Detheux, CEO Iteos Therapeutics :
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
Pierre-Antoine Mariage, co-CEO Botalys :
"VIVES trusted us at an early stage. In addition to their financial investment, they offer us a regular and wise coaching from their experts while respecting...
Philippe Mengal, past CEO Greenwatt :
"The support of VIVES was essential because it was first of all a demonstration of confidence at a very early stage of the company just out of UCL Laboratories...
LMO (Luxembourg & UK) and In-Space Missions Ltd (UK) have partnered to explore the use of small satellite platforms for space-based Space Domain Awareness (SDA) as part of LMO’s AUREA (Autonomous
New funding will support the rapid growth of Aphea.Bio, solidifying its position as a frontrunner in biological product development for agriculture.
Gent, Belgium, 11 July 2023 – Aphea.Bio, a Belgium